Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
NPM1
Name:
nucleophosmin 1
Location:
05q35.1
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT01066286 | Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia | View | |
| NCT01296178 | PETHEMA-LMA10 Treatment of Acute Myeloblastic Leukemia AML in Patients Less Than or Equal to 65 Years | View | |
| NCT03280888 | Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia CMML | View | |
| NCT05304156 | Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy A THEMA Study | View | |
| NCT05339204 | The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission | View | |
| NCT05541224 | A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers | View | |
| NCT02450877 | A Study of Safety Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia | View | |
| NCT06429670 | Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and RelapseRefractory | View | |
| NCT01237808 | Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | View | |
| NCT01623518 | A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NPM1 | View | |
| NCT00993083 | A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NPM1 In Healthy Adults | View | |
| NCT04689815 | Oral Arsenic Trioxide for NPM1-mutated AML | View | |
| NCT01770158 | Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia AML Patients With Measurable Minimal Residual Disease MRD- a Non-interventional Study NIS | View | |
| NCT01465035 | A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NPM1 and Seasonal Influenza Vaccine | View | |
| NCT01835288 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | View | |
| NCT02014168 | Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NPM1 and Viroflu Seasonal Influenza Vaccine | View | |
| NCT01818362 | A Phase I Study of Candidate Influenza Vaccines MVA-NPM1 and ChAdOx1 NPM1 | View | |
| NCT03300362 | Improved Novel VaccIne CombinaTion InflUenza Study | View | |
| NCT05521087 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With RelapsedRefractory Acute Leukemias | View | |
| NCT03880474 | Efficacy of Candidate Influenza Vaccine MVA-NPM1 in Adults | View | |
| NCT04311060 | Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia a Prospective Multicentric Study | View | |
| NCT03277456 | A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NPM1 | View | |
| NCT04931992 | Outcome of Patients With CBF andor NPM1-mutated AML in First Molecular Relapse | View | |
| NCT04867928 | Venetoclax and Azacitidine for the Management of Molecular RelapseProgression in Adult NPM1-mutated Acute Myeloid Leukemia | View | |
| NCT03883113 | Efficacy of MVA-NPM1 in the Influenza H3N2 Human Challenge Model | View | |
| NCT05020665 | Entospletinib Plus Intensive InductionConsolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML | View | |
| NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | View | |
| NCT05153330 | Study of BMF-219 a Covalent Menin Inhibitor in Adult Patients With AML ALL With KMT2A MLL1r NPM1 Mutations DLBCL MM and CLLSLL | View | |
| NCT05063123 | Study to Assess an Interphase Cycle With Flotetuzumab | View | |
| NCT06001788 | Safety and Tolerability of Ziftomenib Combinations in Patients With RelapsedRefractory Acute Myeloid Leukemia | View | |
| NCT04369287 | Prevalence and Clinical Effect of IDH12 Mutations in Patients With Acute Myeloid Leukemia | View | |
| NCT06222580 | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | View | |
| NCT04988555 | A Study of DSP-5336 in Relapsedrefractory AML ALL with or Without MLL Rearrangement or NPM1 Mutation | View | |
| NCT06268574 | Safety and Efficacy of RVU120 for Treatment of RelapsedRefractory AML | View | |
| NCT06313437 | Revumenib in Combination With 73 Midostaurin in AML | View | |
| NCT05326516 | A Study of Revumenib in Combination With Chemotherapy in Participants With RR Acute Leukemia | View | |
| NCT06649227 | Study Investigating the Safety of CD19 CAR-T Cells in RelapsedRefractory AML Expressing CD19 | View | |
| NCT06652438 | Revumenib in Combination With Azacitidine Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | View | |
| NCT06440135 | Ziftomenib Maintenance Post Allo-HCT | View | |
| NCT05453903 | A Study of Bleximenib in Combination With Acute Myeloid Leukemia AML Directed Therapies | View | |
| NCT06611839 | Venetoclax and Ivosidenib Combined with Chemotherapy in IDH1 Mutated AML | View | |
| NCT06575296 | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | View | |
| NCT05738538 | Expanded Access to Ziftomenib | View | |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With VenetoclaxAzacitidine Venetoclax or 73 in Patients With AML | View | |
| NCT00893399 | Study of Chemotherapy in Combination With All-trans Retinoic Acid ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia AML and Mutant Nucleophosmin-1 NPM1 Gene Mutation | View | |
| NCT00942071 | A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NPM1 in Healthy Adults | View | |
| NCT05886049 | Testing the Addition of an Anti-cancer Drug SNDX-5613 to the Standard Chemotherapy Treatment Daunorubicin and Cytarabine for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLLKMT2A Gene | View | |
| NCT05904106 | Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML | View | |
| NCT05918692 | A Phase 1 Study of BMF-500 in Adults With Acute Leukemia | View | |
| NCT05918913 | Expanded Access Program for Revumenib | View | |
| NCT06226571 | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | View | |
| NCT06262438 | CHIP-AML22Quizartinib Quizartinib Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD and NPM1wt AML Patients | View | |
| NCT06376162 | Ziftomenib in Combination With Chemotherapy for Children With RelapsedRefractory Acute Leukemia | View | |
| NCT06424340 | MB-dNPM1-TCR1 in RelapsedRefractory AML | View | |
| NCT05347511 | Study of the Pronostic Impact of Immunohistochemical Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma | View | |
| NCT06635681 | Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML | View | |
| NCT03311815 | Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing NGS in Patients Diagnosed With Acute Myeloid Leukemia | View | |
| NCT03769532 | MRD-guided Treatment in NPM1mut AML Patients | View | |
| NCT04065399 | A Study of Revumenib in RR Leukemias Including Those With an MLLKMT2A Gene Rearrangement or NPM1 Mutation | View |